EGFR and non-small cell lung carcinoma: The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) April 2022 recommend osimertinib for patients with completely resected stage III epidermal growth factor receptor (EGFR) mutation positive NSCLC who received previous adjuvant CT or are ineligible to receive platinum based CT (9).